ESC 365 - Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension

ESC Premium Access

Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension

Session: Drug treatment in hypertension - New insights

Topic: Treatment

Speaker: Ms P. Danaietash (Allschwil, CH)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Ms Parisa Danaietash

Idorsia Pharmaceuticals, Allschwil (Switzerland)

0 follower

3 more presentations in this session

State of the Art - Drug treatment in hypertension: unmet needs

Speaker: Professor B. Williams (London, GB)

Can anti-hypertensive thiazide diuretics also reduce fragility fracture risk?

Speaker: Doctor J. Sousa (Porto, PT)

New targets for blood pressure lowering drugs

Speaker: Professor G. Parati (Milan, IT)

Access the full session

Drug treatment in hypertension - New insights

Speakers: Ms P. Danaietash, Professor B. Williams, Doctor J. Sousa, Professor G. Parati

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources